Keyword: Darzalex

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.

Darzalex has become the first biologic approved for newly diagnosed multiple myeloma patients who are eligible for stem cell transplant.

Amgen’s Kyprolis is finally on track for blockbuster status this year, and new data in tandem with J&J's Darzalex could help boost it even further.

The FDA defied an expert panel's call to delay approval on safety issues, at least until phase 3 data debuts later this year.

J&J's Darzalex hasn’t stopped rolling since hitting the market. After picking up its first nod in previously untreated patients last May, the drug has added another.

Right now, the first infusion of J&J's Darzalex can take between seven and eight hours. But data on a new formulation could be a game changer.

J&J's Darzalex is on track to nab a second first-line myeloma nod in the U.S., but its reimbursement journey in England hasn't been so smooth.

Competition and discounting are unsurprisingly taking a toll on J&J’s older drugs. But cardiovascular product Xarelto is also on that list.

J&J's Darzalex made multiple myeloma history in May with an FDA nod in newly diagnosed patients. And now, it’s looking for a repeat.